Ventilator-Associated Pneumonia, Percutaneous Tracheostomy, and Antimicrobial Prophylaxis
To the Editor:
Dr. Schultz raises pertinent concerns about the use of antimicrobial prophylaxis in patients who undergo percutaneous tracheostomies, and disagrees with our interpretation of the findings of ventilator-associated pneumonia (VAP) after percutaneous tracheostomy. 1 Tracheostomy is an elective surgical procedure in patients with contaminated tracheal mucosa (present in all intubated patients). Therefore, we believe that administration of a ␤-lactam in the interval of 2 h before the time of surgical incision is a correct indication. 2 Antimicrobial prophylaxis should cover potential pathogens to decrease surgery-related infections. The most frequent isolates colonizing our patients prior to tracheotomy were nonfermentative Gram-negative bacilli, with Pseudomonas aeruginosa being identified as the most frequent responsible pathogen. Another patient acquired bacteremia by P aeruginosa during the procedure. 1 Based on these findings, we suggested that surgical antimicrobials prescribed for tracheotomy prophylaxis in intubated patients should be active against P aeruginosa.
Dr. Schultz also expressed concern that the incidence of VAP in patients with tracheotomy was not compared to patients not receiving a tracheostoma. The overall incidence of VAP in our ICU was 9.6% of intubated patients in the study period. In the current article, 18.1% of patients acquired VAP after percutaneous tracheotomy. These episodes occurred a median of 7 days after intubation, and most episodes occurred within the first 5 days after the procedure (Table 2) . 1 This percentage notably exceed the Ͻ 1% cumulative risk of acquiring pneumonia per day of mechanical ventilation, which is considered standard in intubated patients. 3 Finally, Dr. Schultz indicates that antibiotic use in many patients before the procedure may have predisposed to the high incidence of VAP. However, in a cohort study 4 focusing on episodes of pneumonia, prior antibiotic use showed a protective effect (relative risk, 0.1; 95% confidence interval, 0.01 to 0.71) within the first days after intubation. These findings agree with observations reported by Sirvent et al 5 using a prophylactic antibiotic approach. Similarly, Cook et al 6 estimated that exposure to antibiotics was associated with a risk ratio of 0.37 (95% confidence interval, 0.27 to 0.51) for development of VAP. A recent review article by Bonten et al 7 confirmed these reports. Antibiotic exposure protects against pneumonia development within the first days of the intubation manipulation, especially communications to the editor against flora present in the colonized airways, suggesting that risk factors vary depending of the exposure to risk (ie, length of ventilation). 8 Our opinion on antimicrobial prophylaxis for VAP has been clearly stated in a recent editorial, 9 and a randomized clinical trial to assess the effect of single-dose antibiotic administration as prophylaxis for VAP is highly recommended. Unfortunately, such evidence is lacking. Dr. Schultz suggests not using antimicrobial prophylaxis for percutaneous tracheotomies. However, as indicated before, prophylaxis for surgical neck procedures in intubated patients with colonized tracheal mucosa has a level 1 evidence. Until such studies are available, the extremely high incidence of VAP in the first days after the procedure, the distribution of pathogens, and the low predictive value of tracheal aspirates prior to tracheostomy 1 suggest that prescription of a single dose of an antipseudomonal agent prior to the percutaneous tracheotomy is the most pertinent policy. 
Surgical Stress in ARDS Open-Lung Biopsy
We read with great interest the recent case series by Patel and colleagues (January 2004). 1 In their discussion about complications after open-lung biopsy in patients with ARDS, however, they did not refer to the contribution of surgical stress to ARDS. Major surgery, including cardiovascular surgery with cramping of the aorta and resulting in ischemia/reperfusion of the lower body, sometimes causes a systemic inflammatory response leading to the development of fatal organ-system dysfunction such as ARDS. 2, 3 Tumor necrosis factor or other cytokines and chemokines play important roles in systemic inflammatory response syndrome. 3 Enhanced release of proinflammatory cytokines and chemokines results in a trigger for the production of numerous other inflammatory mediators such as nitric oxide, adhesion molecules, and eicosanoids. 2 Rajimakers et al 4 demonstrated the strong correlation between an increase in circulatory interleukin-8 and pulmonary microvascular permeability related to aortic surgery. Indeed, we previously confirmed the pivotal roles of proinflammatory cytokines in murine acute lung injury induced by bacterial endotoxin, a similar condition for ARDS in humans. 5 In particular, proinflammatory chemokines such as macrophage inflammatory protein-1, macrophage chemoattractant protein-1, and keratinocyte chemoattractant in the lung paralleled the magnitude of lung injury and neutrophilic inflammation in our experiments. [5] [6] [7] Therefore, surgery itself may aggravate ARDS. As Patel and colleagues 1 concluded, clinicians should give careful consideration to the selection of patients with ARDS.
